Robin Tumlinson, PharmD, BCOP, discusses how biomarker-guided treatment and increasingly complex toxicity profiles are expanding oncology pharmacists’ responsibilities in bladder cancer care.
Robin Tumlinson, PharmD, BCOP
Advertisement
Articles by Robin Tumlinson, PharmD, BCOP
In an interview with Pharmacy Times, Robin Tumlinson, PharmD, BCOP, clinical pharmacist specialist in genitourinary oncology at Vanderbilt University Medical Center, discussed recent developments reshaping bladder cancer treatment across disease stages.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
Advertisement
Latest Updated Articles
New Biomarkers and Toxicities Expand Pharmacists’ Role in Bladder CancerSeptember 18th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
4
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
5